Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy.

Frohlich1, Aristizabal, Soria

  • 1Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA

Journal of Cardiovascular Pharmacology and Therapeutics
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Some endocrine-ophthalmological aspects.

Clinica hispanica·2010
Same author

Marcus Gunn phenomenon and voluntary nystagmus.

Archivos de la Sociedad Oftalmologica Hispano-Americana·2010
Same author

Molecular structure of a heptadentate cogwheel: C7Me7+ is not planar

The Journal of organic chemistry·2000
Same author

Colin johnston celebration

Hypertension (Dallas, Tex. : 1979)·2000
Same author

Conformal boundary conditions and three-dimensional topological field theory

Physical review letters·2000
Same author

Determination of the magnetic symmetry of hexagonal manganites by second harmonic generation

Physical review letters·2000
Same journal

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Norepinephrine Versus Dopamine as Vasoactive Therapy in Cardiogenic Shock: Association With 28-Day Mortality in a Retrospective Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Comparative Effectiveness of Renin-Angiotensin System Inhibitors in Heart Failure With Nonreduced Ejection Fraction: A Multicenter Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Shared Genetic Liability Between Heart Failure and Myocardial Infarction Revealed by Genome-Wide Cross-Trait Analysis.

Journal of cardiovascular pharmacology and therapeutics·2026
See all related articles

Reversing left ventricular hypertrophy (LVH) in hypertension may reduce risk, but demonstrating this benefit independently of blood pressure changes requires further investigation. Ischemic changes, not arrhythmias, appear more valuable for assessing risk reduction from LVH reversal.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Trials

Background:

  • Hypertension is a major risk factor for left ventricular hypertrophy (LVH).
  • Demonstrating risk reduction from LVH reversal independent of blood pressure reduction is crucial.
  • Previous studies have not fully elucidated the independent benefits of LVH reversal.

Purpose of the Study:

  • To assess the feasibility of demonstrating risk reduction from reversing LVH in hypertensive patients.
  • To investigate whether risk reduction from LVH reversal is independent of blood pressure reduction.
  • To identify potential markers for risk reduction during LVH reversal.

Main Methods:

  • A feasibility study involving 15 hypertensive patients with LVH.
  • Utilized 48-hour Holter monitoring, exercise treadmill tests, thallium scintigraphy, and coronary angiography.

Related Experiment Videos

  • Patients were treated with quinapril (10 mg) for 3 months.

    • Main Results:

    • Significant reduction in mean arterial pressure (125 +/- 3.1 to 103 +/- 1.9 mmHg) and LVH index (125 +/- 6.4 to 104 +/- 4.9).
    • Left ventricular function was preserved.
    • No significant change in arrhythmias; however, 4 patients developed ST-segment changes prior to LVH reversal, which resolved in 3 patients post-reversal.

    Conclusions:

    • Ischemic changes may be more indicative of risk reduction than arrhythmias during LVH reversal.
    • Preliminary data suggest challenges in demonstrating risk reduction from LVH reversal.
    • More sensitive techniques are needed to accurately assess risk reduction associated with LVH reversal.